Month: March 2024

Geneva, Switzerland, March 21, 2024 (GLOBE NEWSWIRE) — Schedules Conference Call and Webcast for Friday, March 22 at 9:00am ET (2:00 pm CET)Reports 29% increase in revenue and 43% higher gross profit, as compared to FY 2022. Ends the year with a strong cash position of $6.9 million. Continues to tap into new revenue streams through increased investments in next generation post-quantum technologies. Aims to launch these groundbreaking products by late 2025 or early 2026. SEALCOIN, expected to launch in Q2 2024, is expected to be transformational in the Machine-to-Machine (M2M) economy. Implementation of QUASARS project is paving the way for the Post Quantum Cryptography era. Continues geographic expansion: currently in negotiations to establish three new OSAT (Open Semiconductor Assembly and Test) centers in Spain, the USA,...

VANCOUVER, British Columbia, March 21, 2024 (GLOBE NEWSWIRE) — Central 1 Credit Union (“Central 1” or the “organization”) reported a consolidated net income of $25.4 million for the year ended December 31, 2023, compared to a net loss of $69.6 million in 2022. 2023 consolidated results compared to 2022:Net income of $25.4 million, compared to a net loss of $69.6 million in 2022. Net interest income of $54.3 million, compared to a net interest income of $75.9 million in 2022. Net fair value gain1 of $28.3 million, compared to a net fair value loss1 of $143.0 million in 2022. Return on average equity2 of 3.6 per cent, compared to negative 9.8 per cent in 2022. Total assets of $11.2 billion, compared to $11.9 billion in 2022.Central 1’s 2023 results reflect a strong year across business lines driven by a mix of fee revenue, higher...

DALLAS, March 21, 2024 (GLOBE NEWSWIRE) — Instil Bio, Inc. (“Instil”) (Nasdaq: TIL), a clinical-stage biopharmaceutical company focused on developing a pipeline of novel therapies, today reported its fourth quarter and full year 2023 financial results and provided a corporate update. Recent Highlights:Announced entering into a strategic collaboration to develop an autologous folate receptor α (FRα)-CoStAR enhanced TIL for a potential investigator-initiated trial (IIT) in non-small cell lung cancer in ChinaAnnounced a strategic update to the ITIL-306 program, including closure of Instil’s UK manufacturing and cessation of ITIL-306 clinical trial activitiesExploring opportunities to in-license/acquire and develop novel therapeutic candidates in diseases with significant unmet medical needCash runway expected beyond 2026Fourth...

TORONTO, March 21, 2024 (GLOBE NEWSWIRE) —  ECN Capital Corp. (TSX: ECN) (“ECN Capital” or the “Company”) today reported financial results for the three-month period and year ended December 31, 2023. For the three-month period ended December 31, 2023, ECN Capital reported Adjusted net (loss) applicable to common shareholders from continuing operations of ($13.5) million or ($0.05) per share (basic) versus $0.5 million or $0.00 per share (basic) for the previous three-month period and $4.1 million or $0.02 per share (basic) for the same period last year. “While 2023 was a difficult year, ECN and its businesses have resumed a growth trajectory in 2024”, said Steven Hudson, CEO of ECN Capital Corp. “We have substantially resolved the challenges that affected performance last year and successfully transitioned management with new leadership...

VANCOUVER, British Columbia, March 21, 2024 (GLOBE NEWSWIRE) — Diversified Royalty Corp. (TSX: DIV and DIV.DB.A) (the “Corporation” or “DIV”) is pleased to announce its financial results for the three months (“Q4 2023”) and year ended December 31, 2023. HighlightsThe weighted average organic royalty growth1 of DIV’s diversified royalty portfolio was 6.8% in Q4 2023 and 8.4% for the year ended December 31, 2023, compared to 8.6% in Q4 2022 and 11.6% for the year ended December 31, 2022. Revenue was $16.4 million in Q4 2023 and $56.5 million for the year ended December 31, 2023, up 28.9% and 25.0%, respectively, compared to $12.7 million in Q4 2022 and $45.2 million for the year ended December 31, 2022. Adjusted revenue1 of $17.7 million in Q4 2023 and $61.6 million for the year ended December 31, 2023, up 26.4% and 22.7%, respectively,...

Lead program, TIDAL-01, advancing in Phase 1 trials with initial clinical data expected in mid-2024 Promising preclinical data highlighting Turnstone’s novel Selected TIL programs for solid tumors presented at SITC 2023 Further strengthened Scientific Advisory Board with appointment of internationally recognized cancer immunotherapy expert, Dr. Jeffrey S. Weber SAN DIEGO, March 21, 2024 (GLOBE NEWSWIRE) — Turnstone Biologics Corp. (“Turnstone” or the “Company”) (Nasdaq: TSBX), a clinical-stage biotechnology company developing a differentiated approach to treat and cure patients with solid tumors by pioneering selected tumor-infiltrating lymphocyte (Selected TIL) therapy, today reported financial results for the fourth quarter and full year ended December 31, 2023, and provided recent business highlights. “2023 marked a transformative...

~ Glocal Ruling from Arbitral Tribunal in Favor of Company for up to $110.2 Million in Damages ~ ~ Sale of Cloudbreak Health Business Closed on March 15, 2024 ~ ~ Gross Cash Proceeds of $180 Million from the Cloudbreak Sale Will Be Used to Pay Down Debt, Including All of the Company’s $115 Million 2026 Notes and a Substantial Portion of its $57.2 Million 2025 Notes ~ ~ Continues Simplification Strategy Focused on Profitable TTC Behavioral Healthcare Business ~ DELRAY BEACH, Fla., March 21, 2024 (GLOBE NEWSWIRE) — UpHealth, Inc. (“we,” “UpHealth,” or the “Company”) (OTC: UPHL) today provided a corporate update and announced financial results for the fourth quarter and full year ended December 31, 2023. “In short, 2023 was a challenging, yet transformative, year for UpHealth, as we continued to take steps to stabilize the business,”...